A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
Clinical trial NCT03980002 · RECRUITING
Trial details
- NCT number
- NCT03980002
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-05-15
- Primary completion
- 2022-12-15
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.